NZ515359A - Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol - Google Patents

Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol

Info

Publication number
NZ515359A
NZ515359A NZ515359A NZ51535900A NZ515359A NZ 515359 A NZ515359 A NZ 515359A NZ 515359 A NZ515359 A NZ 515359A NZ 51535900 A NZ51535900 A NZ 51535900A NZ 515359 A NZ515359 A NZ 515359A
Authority
NZ
New Zealand
Prior art keywords
heroin
alcohol
reducing consumption
weight
microsphere compositions
Prior art date
Application number
NZ515359A
Other languages
English (en)
Inventor
Thomas R Tice
Jay K Staas
Teresa M Ferrell
Original Assignee
Southern Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Res Inst filed Critical Southern Res Inst
Publication of NZ515359A publication Critical patent/NZ515359A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ515359A 1999-04-09 2000-04-08 Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol NZ515359A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12847799P 1999-04-09 1999-04-09
PCT/US2000/009438 WO2000061147A1 (en) 1999-04-09 2000-04-08 Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol

Publications (1)

Publication Number Publication Date
NZ515359A true NZ515359A (en) 2002-10-25

Family

ID=22435553

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ515359A NZ515359A (en) 1999-04-09 2000-04-08 Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol

Country Status (25)

Country Link
US (1) US6306425B1 (2)
EP (1) EP1171132B1 (2)
JP (2) JP4995371B2 (2)
KR (1) KR100621261B1 (2)
CN (1) CN1210031C (2)
AT (1) ATE262906T1 (2)
AU (1) AU780852B2 (2)
BR (1) BR0009639A (2)
CA (1) CA2369302C (2)
CZ (1) CZ20013636A3 (2)
DE (1) DE60009477T2 (2)
DK (1) DK1171132T3 (2)
EA (1) EA004734B1 (2)
ES (1) ES2218147T3 (2)
HK (1) HK1047245B (2)
HU (1) HUP0200838A3 (2)
IL (2) IL145802A0 (2)
MX (1) MXPA01010185A (2)
NO (1) NO328647B1 (2)
NZ (1) NZ515359A (2)
PL (1) PL196930B1 (2)
PT (1) PT1171132E (2)
TR (1) TR200102880T2 (2)
UA (1) UA79921C2 (2)
WO (1) WO2000061147A1 (2)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US7919119B2 (en) 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
AU2001223396A1 (en) * 2000-02-01 2001-08-14 Disetronic Licensing Ag Container and device for administering a substance
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
CN1610551A (zh) * 2001-07-06 2005-04-27 恩德制药公司 用作止痛剂的6-羟基羟吗啡酮的肠胃外给药
KR20030048026A (ko) 2001-07-06 2003-06-18 펜웨스트 파머슈티칼즈 컴파니 옥시모르폰의 서방형 제제
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7094369B2 (en) 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
US7131997B2 (en) 2002-03-29 2006-11-07 Scimed Life Systems, Inc. Tissue treatment
US7053134B2 (en) 2002-04-04 2006-05-30 Scimed Life Systems, Inc. Forming a chemically cross-linked particle of a desired shape and diameter
US7041320B1 (en) 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
US7157102B1 (en) 2002-05-31 2007-01-02 Biotek, Inc. Multi-layered microcapsules and method of preparing same
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
US7449236B2 (en) 2002-08-09 2008-11-11 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US7842377B2 (en) * 2003-08-08 2010-11-30 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US20040109886A1 (en) * 2002-08-27 2004-06-10 Larry Rigby Methods and apparatus for transdermal delivery of abusable drugs with a deterrent agent
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US7588825B2 (en) 2002-10-23 2009-09-15 Boston Scientific Scimed, Inc. Embolic compositions
US7883490B2 (en) 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
EP1610674A4 (en) * 2003-03-13 2008-05-21 Cheryl M Burgess METHODS OF ADMINISTERING MATERIAL TO PATIENT TO OBTAIN DERMAL IMPROVEMENT
US7279579B2 (en) * 2003-06-04 2007-10-09 Alkermes, Inc. Polymorphic forms of naltrexone
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US20050031713A1 (en) * 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP3A4 sensitive patients
US7976823B2 (en) 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
BRPI0414907A (pt) * 2003-09-30 2006-11-07 Acusphere Inc formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
US7901770B2 (en) 2003-11-04 2011-03-08 Boston Scientific Scimed, Inc. Embolic compositions
HRP20090363T1 (hr) * 2004-02-23 2009-08-31 Euro-Celtique S.A. Transdermalni injektor opioida rezistentan na zlouporabu
US7736671B2 (en) 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
US20050245461A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
US7919499B2 (en) 2004-04-22 2011-04-05 Alkermes, Inc. Naltrexone long acting formulations and methods of use
US7311861B2 (en) 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
US7727555B2 (en) 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
US7858183B2 (en) 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US7963287B2 (en) 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
CN1872063B (zh) * 2005-06-03 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 纳美芬或其盐的长效注射用微球或组合物及其制备方法
US9463426B2 (en) 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
US7947368B2 (en) 2005-12-21 2011-05-24 Boston Scientific Scimed, Inc. Block copolymer particles
US7501179B2 (en) 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
EP1810714A1 (de) * 2006-01-19 2007-07-25 Holger Lars Hermann Verwendung einer Kombination von Heroin und Naloxon zur Drogensubstitution
RU2310449C1 (ru) * 2006-05-17 2007-11-20 Руслан Геннадьевич Нервалев Способ лечения опиоидной и/или алкогольной зависимости
EP2214672B1 (en) * 2007-10-18 2012-10-17 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
US8486448B2 (en) 2007-12-17 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
AU2009327312A1 (en) 2008-12-16 2011-08-04 Labopharm Europe Limited Misuse preventative, controlled release formulation
US20100196436A1 (en) * 2009-01-30 2010-08-05 Gooberman Lance L Implants containing disulfiram and an anti-inflammatory agent
US8791093B2 (en) * 2009-05-29 2014-07-29 Lance L. Gooberman Pharmaceutical delivery systems for treatment of substance abuse and other addictions
US20110223244A1 (en) * 2010-03-09 2011-09-15 Elan Pharma International Limited Alcohol resistant enteric pharmaceutical compositions
RU2476209C1 (ru) * 2012-02-29 2013-02-27 Станислав Анатольевич Кедик Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
BR112016002342A8 (pt) 2013-08-06 2018-01-23 Dong Kook Pharm Co Ltd microesfera entecavir, método para preparação de uma microesfera entecavir, e, composição farmacêutica
WO2016013993A1 (en) * 2014-07-25 2016-01-28 Imuneks Farma Llac Sanayi Ve Ticaret A.Ş. Stable preservative free ophthalmic formulations of opioid antagonists
AU2019362730B2 (en) 2018-10-15 2022-10-20 Chong Kun Dang Pharmaceutical Corp. Injectable long-acting naltrexone microparticle compositions
GR1009871B (el) * 2019-07-30 2020-11-12 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει μικροσφαιριδια ναλτρεξονης και μεθοδος παρασκευης αυτου
US20210059943A1 (en) * 2019-09-04 2021-03-04 Buffalo Pacific LLC Systems and methods addressing multiple aspects to provide a comprehensive recovery program for addictions, chronic conditions and diseases
WO2022191615A1 (ko) * 2021-03-09 2022-09-15 (주)인벤티지랩 저용량 날트렉손을 함유하는 자가면역질환 예방 또는 치료용 서방성 제제 및 이를 이용한 방법
CA3236690A1 (en) * 2021-11-18 2023-05-25 Ju Hee Kim Sustained-release injectable composition containing naltrexone and method for preparing same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4568559A (en) 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
US4623588A (en) 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
US4981696A (en) 1986-12-22 1991-01-01 E. I. Du Pont De Nemours And Company Polylactide compositions
DE3710175A1 (de) 1987-02-12 1988-08-25 Hoechst Ag Mehrteilige implantierbare arzneizubereitung mit langzeitwirkung
FR2618674B1 (fr) 1987-07-30 1990-06-15 Ire Celltarg Sa Microparticules comportant un polymere biodegradable controlant la liberation d'un principe actif antimalarique, compositions pharmaceutiques en comprenant et procede de preparation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
DE3734223A1 (de) * 1987-10-09 1989-04-20 Boehringer Ingelheim Kg Implantierbares, biologisch abbaubares wirkstofffreigabesystem
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US4902515A (en) 1988-04-28 1990-02-20 E. I. Dupont De Nemours And Company Polylactide compositions
WO1990013361A1 (en) 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
CA2290788A1 (en) * 1997-05-20 1998-11-26 Suchitra Krishnan-Sarin Substance dependence treatment using opiate antagonists and serotonin compounds
JPH11269094A (ja) * 1998-01-16 1999-10-05 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途

Also Published As

Publication number Publication date
JP2010031036A (ja) 2010-02-12
HK1047245A1 (en) 2003-02-14
EA200101062A1 (ru) 2002-04-25
BR0009639A (pt) 2002-02-05
CN1210031C (zh) 2005-07-13
EP1171132A1 (en) 2002-01-16
NO20014896L (no) 2001-12-07
WO2000061147A1 (en) 2000-10-19
HK1047245B (zh) 2006-03-03
IL145802A0 (en) 2002-07-25
HUP0200838A3 (en) 2005-07-28
KR100621261B1 (ko) 2006-09-13
ES2218147T3 (es) 2004-11-16
CA2369302A1 (en) 2000-10-19
CA2369302C (en) 2007-09-25
DE60009477D1 (de) 2004-05-06
PL350548A1 (en) 2002-12-16
PL196930B1 (pl) 2008-02-29
JP2002541202A (ja) 2002-12-03
HUP0200838A2 (hu) 2002-07-29
PT1171132E (pt) 2004-07-30
JP4995371B2 (ja) 2012-08-08
NO328647B1 (no) 2010-04-19
TR200102880T2 (tr) 2002-03-21
UA79921C2 (en) 2007-08-10
DK1171132T3 (da) 2004-07-12
IL145802A (en) 2009-02-11
AU4220300A (en) 2000-11-14
ATE262906T1 (de) 2004-04-15
CZ20013636A3 (cs) 2002-03-13
CN1354664A (zh) 2002-06-19
KR20020011975A (ko) 2002-02-09
DE60009477T2 (de) 2005-02-24
EA004734B1 (ru) 2004-08-26
US6306425B1 (en) 2001-10-23
EP1171132B1 (en) 2004-03-31
AU780852B2 (en) 2005-04-21
NO20014896D0 (no) 2001-10-08
MXPA01010185A (es) 2003-07-21

Similar Documents

Publication Publication Date Title
NZ515359A (en) Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
SI0729357T1 (en) Microencapsulated 1,2-benzazoles
GEP20074022B (en) Pharmaceutical formulations comprising oxycodone and naloxone
CA2392013A1 (en) Analgesic compositions containing buprenorphine in combination with naloxone, naltrexone or nalmefene
PL343829A1 (en) Adhesive microsphere drug delivery composition
EP1695708A3 (en) Pharmaceutical composition
ATE280579T1 (de) Injizierbare buprenorphinhaltige mikrosphärenzusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum
WO2001078725A3 (en) Modified release formulations containing a hypnotic agent
WO2001047498A3 (en) Hydrogel-driven layered drug dosage form comprising sertraline
WO2003000237A3 (en) Biodegradable polymer coompositions
MXPA04003742A (es) Farmaco conteniendo 3-(3-dimetilamino-1-etil-2-metil-propil)fenol con liberacion lenta de la sustancia activa.
ES2172915T3 (es) Formulaciones bucodentales que contienen nanofibrillas de celulosa esencialmente amorfas.
NZ508691A (en) Encapsulated long chain alcohols and use in reducing cholesterol
CA2340898A1 (en) Compositions and methods for treating intracellular infections
EP1621207A3 (en) Mixture of defibrotide and G-CSF, and its use for activating haematopoietic progenitors
CA2322229A1 (en) Compositions comprising heparin and soluble tnf receptors for inhibition of tnf activity
WO2001085188A3 (en) Use of echinacea as a hematinic agent
WO2002017877A3 (en) Controlled release pharmaceutical pellet compositions for reducing side effects of drugs
ATE102934T1 (de) Fluorierte flavon-essigsaeure.
UA86929C2 (ru) Композиция с контролируемым высвобождением
CA2216371A1 (en) Novel "burst-free" sustained release poly-(lactide/glycolide) microspheres

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: BROOKWOOD PHARMACEUTICALS INC., US

Free format text: OLD OWNER(S): SOUTHERN RESEARCH INSTITUTE

RENW Renewal (renewal fees accepted)